What’s new

• Board to meet on July 7, 2026 to consider bonus share issuance.
• Trading window closed from June 24 to July 9.
• No details on ratio or record date provided.

Why it matters

For a nano-cap, a bonus issue is a rare move that could increase free float and liquidity. It signals management's confidence and is typically viewed positively by the market.

What we’re watching

• The bonus ratio once announced.
• Record date and timeline for credit.
• Market reaction on the board meeting date.

The full read

Mayank Cattle Food has called a board meeting for July 7, 2026 to consider a bonus share issue, a surprise for a ₹110 cr nano-cap with no prior hint of such a move. The trading window is closed from June 24 to July 9. No ratio or record date has been disclosed yet. For a company of this size, a bonus issue can meaningfully boost free float and liquidity, often triggering a positive market reaction. It also signals management's confidence in the business. The open question is the ratio, but the intent alone is a shareholder-friendly signal for a stock that typically flies under the radar.

Primary source: BSE · NSE

What’s new

• Mayank Cattle Food launched 'MAYANK VITA H LIQUID', a multivitamin and mineral supplement for dairy animals.
• The product is part of an ongoing forward integration strategy.
• The company provided no financial projections or investment figures for the new launch.

Why it matters

Product launches are routine for this nano-cap firm, which has introduced similar supplements throughout 2026. Without data on expected revenue or investment, the impact remains speculative.

What we’re watching

• Whether the new product line gains significant market share.
• Any future disclosures on revenue contribution from the supplement portfolio.
• The company's ability to scale its forward integration strategy.

The full read

Mayank Cattle Food has added 'MAYANK VITA H LIQUID' to its product lineup, a multivitamin and mineral supplement for dairy animals. The company, which holds a market capitalization of ₹109 crore, describes the launch as part of its ongoing forward integration strategy.

It is not a surprise.

The firm has rolled out similar supplements throughout 2026, and the filing lacks any quantified financial projections, investment figures, or order values that would allow an investor to gauge the immediate impact on the bottom line. For a company of this size, product launches are standard business developments rather than major shifts in the corporate trajectory. The next test is whether these additions translate into measurable revenue growth.

Primary source: BSE · NSE